Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

verteporfin (Rx)Brand and Other Names:Visudyne

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

lyophylized power for reconstitution

  • 15mg/vial
more...

Macular Degeneration with Classic Subfoveal Choroidal Neovascularization

6 mg/m² IV infusion, total volume 30 mL over 10 min 

Follow with 50 J/cm² of 689 nm laser light on retina at intensity of 600 mW/cm² x 83 sec

Administration

After IV infusion, eyedrops are used to numb eye

Approximately 15 min after infusion & no later than 5 min after eyedrop application, a special ophthalmic lens is placed over eye

Next the cold laser light spot-sized to match treatment area is applied

Central Serous Chorioretinopathy (Orphan)

Designation for the potential treatment of chronic or recurrent central serous chorioretinopathy

Orphan sponsor

  • QLT Inc.; Vancouver, British Columbia, Canada

Safety and efficacy not established

Next

Interactions

Interaction Checker

verteporfin and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Determined

            Visual disturbances

            Injection site reactions  including extravasation and rashes

            Edema

            Hemorrhage

            Inflammation

            Flashes of light

            Severe vision loss (1-4%)

            Photosensitivity

            Headache

            Conjunctivitis

            Dry eyes

            Ocular itching

            Subconjunctival

            Subretinal or vitreous hemorrhage

            Back pain during infusion

            Asthenia

            Fever

            Flu-like syndrome

            Atrial fibrillation

            Hypertension

            Peripheral vascular disorder

            Varicose veins

            Eczema

            Constipation

            GI cancers

            Nausea

            Anemia

            WBC incr/decr

            Elev LFTs

            Albuminuria

            Leukocyte count increase/decrease

            Increased liver function test results

            Albuminuria

            Increased serum creatinine

            Arthralgia

            Arthrosis

            Myasthenia

            Hypesthesia

            Sleep disorder

            Vertigo

            Pharyngitis

            Pneumonia

            Hearing decrease

            Lacrimation disorder

            Prostatic disorder

            Previous
            Next

            Warnings

            Contraindications

            Hypersensitivity, porphyria

            Cautions

            Avoid bright light for 5 days after injection

            Moderate/severe hepatic impairment

            Chest pain, hypersensitivity, and vasovagal reactions reported (observe patient during infusion)

            Use with caution in patients with biliary obstruction

            Patients under anesthesia not studied

            Use in both eyes concurrently not studied (if required, apply to the agressive lesion first followed by the second eye a week later; may apply concurrently to both eyes thereafter)

            Use precaution to avoid extravasation (stop infusion immediately if it occurs)

            Safety and efficacy of use >2 years not established

            Patients who experience severe decrease of vision of 4 lines or more within 1 week, following treatment, should not be retreated, at least until vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by treating physician

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Distributed in milk; not recommended

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Produces oxygen free radicals in presence of light that damage neovascular endothelium, which in turn leads to temporary vessel occlusion

            Pharmacokinetics

            Half-Life: 5-6 hr

            Metabolism: To a small extent by liver and plasma esterases to a diacid metabolite that exhibits pharmacologic activity similar to that of verteporfin

            Excretion: Feces

            Previous
            Next

            Administration

            IV Preparation

            Reconstitute 15 mg drug with 7 mL SWI to obtain a 2 mg/mL opaque dark-green solution

            Protect from light & use within 4 hr

            Further dilute in D5W to match 6 mg/sq.meter dose and infusion volume of 30 mL

            After dilution protect from light & use within 4 hr

            IV Administration

            Infuse the 30 mL solution at rate of 3 mL/min over 10 min

            Large antecubital veins are preferred to avoid extravasation

            Extravasation Management

            Stop infusion immediately & apply cold compresses

            Protect extravasation site from light

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.